Physician profile
Jeffrey Basa
NPI 1992851323
$1,239.05
in general payments reported to CMS, 2019-2025
17 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2021: $15.86 · 2022: $226 · 2023: $129 · 2024: $54.29 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $254.12 | 2022-2023 | Mounjaro |
| Abbvie INC. | $207.57 | 2024-2025 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $114.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $77.22 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $72.95 | 2025 | Breztri |
| Novartis Pharmaceuticals Corporation | $65.69 | 2025 | |
| Edwards Lifesciences Corporation | $58.94 | 2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $51.34 | 2024-2025 | Trelegy Ellipta |
| Pfizer INC. | $36.21 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $32.95 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.06 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $28.51 | 2025 | |
| Abbott Laboratories | $23.57 | 2022 | |
| Amgen INC. | $22.01 | 2024 | Krystexxa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $20.05 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.10 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Basa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.